NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class (Descending) | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00703-5656-01 | 00703-5656 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Aug. 1, 1996 | Jan. 31, 2024 | No Longer Used |
00703-5656-91 | 00703-5656 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | May 16, 2013 | June 30, 2017 | No Longer Used |
55390-0291-01 | 55390-0291 | Etoposide | Etoposide | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | May 1, 1996 | June 30, 2013 | No Longer Used | |
00703-5653-01 | 00703-5653 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Aug. 1, 1996 | In Use | |
00703-5657-01 | 00703-5657 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | May 1, 1997 | Aug. 31, 2022 | In Use |
00703-5657-91 | 00703-5657 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | May 22, 2013 | Nov. 30, 2017 | In Use |
72694-0954-01 | 72694-0954 | Pegaspargase | Oncaspar | 750.0 [iU]/mL | Chemotherapy | Miscellaneous Agent | Enzyme | Intramuscular, Intravenous | Jan. 2, 2020 | In Use | |
54482-0301-01 | 54482-0301 | Pegaspargase | Oncaspar | 750.0 [iU]/mL | Chemotherapy | Miscellaneous Agent | Enzyme | Intramuscular, Intravenous | Feb. 1, 1994 | Nov. 30, 2016 | No Longer Used |
57902-0249-05 | 57902-0249 | Asparaginase | Erwinaze | 10000.0 [iU]/mL | Chemotherapy | Miscellaneous Agent | Enzyme | Intramuscular, Intravenous | Nov. 18, 2011 | July 23, 2021 | No Longer Used |
72694-0515-01 | 72694-0515 | Calaspargase Pegol | Asparlas | 750.0 U/mL | Chemotherapy | Miscellaneous Agent | Enzyme | Intravenous | Sept. 27, 2019 | In Use | |
00944-3810-01 | 00944-3810 | Pegaspargase | Oncaspar | 750.0 [iU]/mL | Chemotherapy | Miscellaneous Agent | Enzyme | Intramuscular, Intravenous | Feb. 1, 1994 | May 16, 2020 | No Longer Used |
68727-0900-03 | 68727-0900 | asparaginase erwinia chrysanthemi (recombinant)-rywn | Rylaze | 20.0 mg/mL | Chemotherapy | Miscellaneous Agent | Enzyme | Intramuscular | June 30, 2021 | In Use | |
81561-0413-05 | 81561-0413 | asparaginase | ERWINASE | 10000.0 [iU]/mL | Chemotherapy | Miscellaneous Agent | Enzyme | Intramuscular, Intravenous | June 1, 2021 | In Use | |
67386-0411-51 | 67386-0411 | Asparaginase (E. coli) | Elspar | Chemotherapy | Miscellaneous Agent | Enzyme | Intramuscular | Jan. 10, 1978 | July 18, 2013 | No Longer Used | |
00024-5150-10 | 00024-5150 | Rasburicase | Elitek | Ancillary Therapy | Metabolic Agent | Enzyme | July 12, 2002 | In Use | |||
00024-5151-75 | 00024-5151 | Rasburicase | Elitek | Ancillary Therapy | Metabolic Agent | Enzyme | June 1, 2006 | In Use | |||
72607-0100-00 | 72607-0100 | tazemetostat | TAZVERIK | 200.0 mg/1 | Chemotherapy | Enzyme Inhibitor | EZH2 | Oral | Jan. 23, 2020 | In Use | |
72187-0101-03 | 72187-0101 | Elacestrant | ORSERDU | 86.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Jan. 27, 2023 | In Use | |
72187-0102-03 | 72187-0102 | Elacestrant | ORSERDU | 345.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Jan. 27, 2023 | In Use | |
68180-0801-36 | 68180-0801 | lapatinib | Lapatinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Sept. 29, 2020 | In Use | |
00078-0671-19 | 00078-0671 | Lapatinib | TYKERB | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Aug. 3, 2016 | In Use | |
00173-0752-00 | 00173-0752 | Lapatinib | TYKERB | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | March 16, 2007 | Nov. 30, 2017 | No Longer Used |
70437-0240-18 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | July 17, 2017 | In Use | |
70437-0240-26 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | July 17, 2017 | In Use | |
70437-0240-33 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | July 17, 2017 | In Use |
Found 10,000 results in 8 milliseconds — Export these results